BW LPG enters into agreement for eight 90’cbm...

(none found in source) BW LPG Limited announces that it has signed a contract for the construction of eight 90’cbm Panamax Very Large Gas Carriers (VLGCs), for a total consideration of about US$940 million, subject to the final technical specifications. The newbuildings are expected to be delivered sequentially from the start of 2029 until the second quarter of 2030. BW LPG is the world’s leading owner and operator of LPG vessels, with a fleet of about 50 Very Large Gas Carriers (VLGCs), including over 20 vessels powered by LPG dual-fuel propulsion technology. The contract is with Hyundai Heavy Industries. BW LPG is associated with BW Group, which controls a fleet of over 400 vessels, including 200 LNG and LPG ships. The announcement was published by Aline Anliker, Head of Corporate Communications, on 30 May 2026 at 5:40pm CEST. The company projects that these Panamax newbuildings represent the most flexible design, enhancing scale, commercial and operational flexibility.

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

(NASDAQ: REPL) Replimune Group, Inc. presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma. The median overall survival (mOS) achieved was 32.9 months in patients with anti–PD-1–failed advanced melanoma. At 3 years, 47.8% of all treated patients remained alive, and 83.5% of responders to RP1 plus nivolumab were alive. The objective response rate (ORR) was 33.6%, with a median duration of response (DOR) of 24.8 months, and 44.8% of responders maintained their response at 3 years. The combination demonstrated a favorable and manageable safety profile over long-term follow-up, with predominantly Grade 1–2 constitutional side effects, no Grade 5 events, and no new safety signals identified. Meaningful survival benefit was observed across all key patient subgroups, including those with varying disease stage, PD-L1 expression status, prior anti–CTLA-4 therapy, and primary or secondary anti–PD-1 resistance. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities.

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

(NASDAQ: MOLN) Molecular Partners AG announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The US multicenter Phase 1/2a study of MP0712 (ClinicalTrials.gov: NCT07278479) is actively recruiting patients with dosing ongoing in the first cohort. MP0712 is a 212 Pb-based Radio-DARPin Therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. DLL3 is present in >85% of tumors of patients with SCLC and other aggressive neuroendocrine tumors, while expression in healthy tissues is low. Molecular Partners and the team of Dr. Mike Sathekge at the Nuclear Medicine Research Institute (NuMeRI) in South Africa presented first patient imaging and dosimetry data on MP0712 at the 8th Theranostics World Congress (TWC) in January 2026. The data, generated with MP0712 carrying the diagnostic isotope 203 Pb, showed specific uptake in tumor lesions. Molecular Partners expects to share initial clinical data from this study in 2026.

Humana Investigation Continued: Kahn Swick &amp; Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM

(NYSE:HUM) Humana Inc. announced its financial results for the fourth quarter and full year 2023, disclosing that its benefits expense ratio increased to approximately 91.4% for the fourth quarter of 2023 and approximately 88% for the full year 2023. The company reported 2023 adjusted EPS of only $26.09 per share, or more than $2 per share less than what the Company had predicted in November 2023. On January 25, 2024, the Company further disclosed a loss for the fourth quarter of 2023 and expected that higher level of medical costs would persist for all of 2024, resulting in expected 2024 adjusted EPS of only $16 per share, a $10 per share decrease from 2023, well below analysts' expectations of $29 per share. The Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws. The Court presiding over the case denied the Company's motion to dismiss the case in part, allowing the case to move forward. Kahn Swick & Foti, LLC continues its investigation into Humana Inc. and is focusing on whether Humana's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.

Good Purpose Investments Announces Frankfurt Stock Exchange Listing and Engages Global One Media

(CSE: GPIN) Good Purpose Investments Inc. announced that its common shares have commenced trading on the Frankfurt Stock Exchange under the ticker symbol 8BS. The FSE listing follows the Company's recent listing on the Canadian Securities Exchange under the ticker symbol GPIN. The Company is actively pursuing an OTC Markets listing and has engaged Global One Media Group Pte. Ltd. to support its digital investor communications strategy. Global One Media will receive an aggregate payment of USD$45,000 for its services, under a 6-month agreement commencing May 21, 2026. Global One Media and its principal and CEO, Bastien Boulay, own 66,667 Common Shares of the Company. The Company describes itself as a sustainability-focused company with an initial portfolio company, Waste2Wear, a wholly-owned subsidiary providing circular textile and product solutions. The company projects that these initiatives form part of a broader strategy to strengthen GPI's visibility, improve investor accessibility, and support long-term shareholder value as it continues building its sustainability-focused growth platform.

Global Compliance Completes Acquisition of Global People's Trust

(CSE: APP, OTCQB: FUAPF) Global Compliance Applications Corp. announced that it has acquired a 100% interest in Global People's Trust LP and Global People's Trust (Management) Limited pursuant to a Share Purchase Agreement with Darrence Hugh Christian. As consideration for the 100% interest in Global People's Trust, the Company has issued the Seller 38,000,000 common shares at a deemed price of $0.015 per Consideration Share. The Consideration Shares are subject to a statutory hold period of 4 months and one day from the date of issuance and a Canadian Securities Exchange mandated hold period, with restrictions including not being sold, transferred, hypothecated or otherwise traded prior to the later of September 13, 2026, ten trading days following the filing of a business acquisition report, or ten trading days following the filing of a CSE-approved Form 5A Annual Listing Summary. Global People's Trust LP is a New Zealand registered Financial Service Provider (FSP) with activities including keeping, investing, administering, or managing money, securities, or investment portfolios on behalf of other persons. The FSP maintains custody accounts in Euro and USD. GCAC specializes in wallet technology, compliance, onboarding and data integrity solutions for regulated industries, and its Efixii platform is developed on an ethereum Layer 2 blockchain. The company projects expected benefits of the Acquisition.

Toogood Gold Signs Definitive Agreement for Option to Earn 100% Interest in the Table Mountain Project, Nevada

(TSXV:TGC) Toogood Gold Corp. announced it has entered into a definitive option agreement dated May 26, 2026, with Orogen Royalties Inc., GenEx Exploration Inc., and Altius Resources Inc., granting Toogood the exclusive right to earn a 100% interest in the Table Mountain Project in Lincoln County, Nevada. The project comprises 184 unpatented lode mining claims totaling 1,538 hectares, with a 4 x 2 km alteration footprint and multiple outcropping Au-Ag-bearing epithermal veins. Toogood will issue an aggregate of 16,683,431 common shares to the Vendors in staged payments over two years, and the Vendors will retain a 3.0% net smelter return royalty, with staged buydown rights to 2.0%. Reconnaissance rock sampling returned gold values up to approximately 2.6 g/t Au and silver values exceeding 50 g/t Ag. Phase 1 exploration has commenced, including soil geochemistry (>6,150 samples), mapping, and geophysical surveys, with a maiden drill program targeted for Q3 2026. The company also intends to settle $110,000 in debt to Canaccord Genuity Corp. by issuing 1,000,000 common shares at a deemed price of $0.11 per share. The company projects that Phase 2 exploration will include CSAMT surveys and further drill-target-focused work.

The FUTR Corporation Reports Financial Results for Q1 2026

(TSXV: FTRC) The FUTR Corporation reported financial results for the three-month period ended March 31, 2026, with total revenue of $1,619,045 compared to $2,145,143 in Q1 2025. Bank processing fees were $1,009,851, an increase of 5.2% over Q1 2025, and enrollment fees were $557,102 compared to $601,576 in Q1 2025. Gross profit was $1,375,588 with a gross margin of 85%, and the company recorded an adjusted loss from operations of $(1,845,483), excluding stock-based compensation of $546,807 and amortization of $331,012. Net loss for the quarter was $(2,642,018), or $(0.02) per share, compared to $(1,645,745), or $(0.04) per share, in Q1 2025. Subsequent to the quarter, the company completed a financing of $4,750,000 and produced 22 new dealer agreements, the highest single-quarter total in its history, building on a base of 160+ active dealers. The company entered into a binding letter of intent with EQIBank, Inc. to establish an agent driven digital bank joint venture (75/25, FUTR controlling), targeting commercial launch in H2 2026. The company projects the commercial launch of the EQIBank joint venture in H2 2026.

CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements

(NASDAQ:CLPS) announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC dated May 27, 2026, indicating that the Company's closing bid price for its common shares fell below $1.00 per share for 30 consecutive trading days. The Company is not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from April 14, 2026 to May 26, 2026, the Company no longer meets the minimum bid price requirement. The Company has been granted a 180-calendar day compliance period, until November 23, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, CLPS's common shares must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by November 23, 2026, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market, or may be subject to delisting. CLPS intends to monitor the closing bid price of its common shares and is committed to taking all reasonable measures, including, but not limited to, implementing a reverse share split of its outstanding common shares, to regain compliance with Nasdaq's minimum bid price requirement.

Canadian Goldfields Appoints Harp Gosal as Director of Capital Markets and Communications

(TSXV: CGM) Canadian Goldfields Discovery Corp. announced the appointment of Harp Gosal as Director of Capital Markets and Communications. The company will issue to Eabametoong First Nation a total of 115,393 common shares at a deemed price of $0.4333 per share for a value $50,000, subject to restrictions on resale for a period of four months and acceptance of the TSX Venture Exchange. The Board of Directors has approved the grant of 400,000 RSUs (subject to approval of the Company's next annual general meeting) with a two-year vesting period and expiry three years from grant, and also granted 400,000 stock options exercisable at $0.455 for a period of 5 years. The Miminiska Gold Project in northwestern Ontario hosts a gold-rich banded iron formation system with multiple high-grade intercepts drilled across the Miminiska and Frond Zones and more than 14 km of underexplored strike extent, supported by approximately 28,000 m of historical drilling. The Newton Gold Property is located within the Swayze Greenstone Belt near Timmins and features historical high-grade gold occurrences. The company projects significant scale potential at Miminiska with mineralization remaining open along strike and at depth. Management is committed to disciplined exploration, systematic discovery and long-term value creation through the advancement of high-quality gold assets in tier-one mining jurisdictions.

New Earth Resources Announces Private Placement

(CSE: EATH) New Earth Resources Corp. announced that it will be conducting a non-brokered private placement to raise aggregate gross proceeds of up to $500,000 through the issuance of up to 4,166,667 units at a price of $0.12 per Unit. Each Unit will consist of one Class A common share and one Share purchase warrant, with each warrant entitling the holder to purchase one Share at a price of $0.18 for five years from the date of issuance. The proceeds from the Offering will be used for general working capital, mineral property exploration, and marketing/IR services. The Lucky Boy Uranium Property, the company's flagship project, is 100% owned and located in Gila County, Arizona, USA, consisting of 14 lode claims spanning approximately 273 acres and contiguous state lease mineral land of approximately 268 acres, totaling approximately 541 acres. The company also has the option to acquire a 100% interest in 23 claims covering approximately 1,102 hectares in the Strange Lake area of Quebec, Canada, and the option to acquire a 100% interest in the Red Wine Rare Earth Project in Labrador, Canada, covering approximately 1,575 hectares. Securities issued under the Offering will be subject to a four month hold period in accordance with applicable Canadian securities laws. The company projects that insiders may participate in the Offering.

Canadian Large Cap Leaders Split Corp. Establishes At-The-Market Equity Program

(TSX:NPS.PR.A) Canadian Large Cap Leaders Split Corp. announced the establishment of an at-the-market equity program (the “ATM Program”) authorizing the issuance of up to $100,000,000 of preferred shares and up to $100,000,000 of class A shares. The ATM Program will be effective until June 28, 2028, unless terminated prior to such date by the Company. Preferred Shares are to provide fixed cumulative preferential quarterly cash distributions of $0.1875 per Preferred Share, representing 7% per annum on a Preferred Share offering price of $10.78 per Preferred Share, until February 28, 2029, subject to extension for successive terms of up to five years. Class A Shares are targeted to provide regular monthly non-cumulative cash distributions of $0.18 per Class A share, representing a yield of 14% per annum on a Class A Share offering price of $15.45 per Class A Share. Ninepoint Partners LP is the Manager, Portfolio Manager and Promoter of the Company, overseeing approximately $8.2 billion in assets under management and institutional contracts. The net proceeds of the ATM Program will be used to invest, on an approximately equally-weighted basis, in a portfolio comprised primarily of equity securities of Canadian Dividend Growth Companies. The company projects that the investment objectives of the Preferred Shares and Class A Shares will be met as described in the prospectus supplement.

Acceleware Ltd. Reports First Quarter 2026 Financial and Operating Results

(TSXV: AXE) Acceleware Ltd. announced its financial and operating results for the three months ended March 31, 2026, reporting revenue of $116,304 and a comprehensive loss of $729,855. R&D expenditures for the quarter were $340,807, and the company had negative working capital of $6.7 million as at March 31, 2026, including cash and cash equivalents of $42 thousand. On April 7, 2026, Acceleware settled outstanding debt to 10% unsecured convertible debenture holders in the aggregate amount of $2,453,640, issuing 12,688,589 units at $0.10 per unit and replacement convertible debentures in the principal amount of $1,184,781. The expected cost to complete the RF XL 2.0 Pilot is approximately $5 million to $6 million including contingency, and the company received conditional approval from the Saskatchewan Petroleum Innovation Incentive program for a transferable royalty credit equal to 25 percent of eligible project costs. The RF XL 2.0 design is complete and ready for manufacturing and deployment, with an estimated 30 percent reduction in per well capital costs compared to RF XL 1.0. The company projects follow-on work from feasibility studies with BHP and expects to complete a paid feasibility study for heap leach heating in 2026.

Battery Mineral Resources Corp. Announces Closing of Final Tranche of LIFE Private Placement Offering

(TSXV:BMR) Battery Mineral Resources Corp. has closed the final tranche of its non-brokered private placement offering, issuing 8,542,030 common shares at a price of $0.20 per share for aggregate gross proceeds of $1,708,406. The company previously closed the first tranche on April 22, 2026, for aggregate gross proceeds of $451,647 and the second tranche on May 7, 2026, for aggregate gross proceeds of $600,000. In total, the company has raised aggregate gross proceeds of $2,760,053 through the sale of 13,800,265 shares under the offering. The shares were issued pursuant to the Listed Issuer Financing Exemption under Part 5A of National Instrument 45-106 and are not subject to resale restrictions under Canadian securities laws. The company paid an arm's length party finder's fees in the amount of $78,024 in connection with the closing of the final tranche. The company intends to use the net proceeds to advance processing plant operations and planned underground development at the Punitaqui Mining Complex in the Coquimbo region of Chile, and for general working capital purposes. The company projects that the intended use of proceeds is more fully described in the offering document dated April 15, 2026.

Centurion Completes $882,150 Debt Reduction Through Shares for Debt and Loan Forgiveness

(TSXV:CTN) Centurion Minerals Ltd. has completed a total debt reduction of $882,150. The Company issued 5,533,333 common shares at a deemed price of $0.075 per share to settle $415,000 of outstanding debt, of which $335,000 was owed to two directors of the Company. Additionally, the same two directors have forgiven a total of $467,150 in long-term loans originally advanced September 2022. These combined transactions reduce the Company's liabilities by $882,150. The company has recently appointed Dr. Dennis LaPoint as President. Centurion Minerals Ltd. is a Canadian-based company with a focus on precious mineral asset exploration and development in the Americas.

ThreeD Capital Inc. Releases Results For the Three and Nine Months Ended March 31, 2026

(CSE:IDK / OTCQB:IDKFF) ThreeD Capital Inc. announced its unaudited results as at and for the three and nine months ended March 31, 2026. As at March 31, 2026, the Company had cash, investments and digital assets of $20.7 million. Net asset value per share was $0.24 as at March 31, 2026, compared to $0.40 as at June 30, 2025. For the three months ended March 31, 2026, net investment and digital asset losses were $ (2,490,890 ), and net loss for the period was $ (3,108,549 ). Total assets as at March 31, 2026 were $22,905,565, and total liabilities were $681,840. The Company reported a basic and diluted loss per common share of (0.03 ) for the three months ended March 31, 2026. The company projects future investments by the Company, as stated in its forward-looking statements.

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

(none found in source) Actinium Pharmaceuticals, Inc. announced it will provide a program update on its first-in-class Actinium-225 (225Ac) antibody radioconjugate, ATNM-400, highlighting new data to be showcased across three presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California. Two presentations will showcase ATNM-400's differentiated profile across prostate cancer and non-small cell lung cancer (NSCLC), while a third will demonstrate the importance of radioconjugate optimization for radiotherapies in the context of the Company's pipeline candidates. As of March 31, 2026, the Company reported stockholders' equity of approximately $2.3 million and had net losses in its last five fiscal years ended December 31, 2025. The Company received a notice from NYSE American indicating non-compliance with the continued listing standards, specifically Section 1003(a)(ii), which requires stockholders' equity of $4.0 million or more. The Company must submit a compliance plan by June 26, 2026, to regain compliance by November 27, 2027. The Company anticipates multiple catalysts for ATNM-400, Actimab-A and Iomab-ACT in 2H:2026 that are expected to demonstrate the clinical potential of these programs.

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

(none found in source) Actinium Pharmaceuticals, Inc. announced that the Canadian Intellectual Property Office (CIPO) has issued Notices of Allowance for two patent applications spanning the Company's Actimab-A and Iomab-ACT programs. The allowances reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwide. The Canadian patent issuing from Application No. 3,087,346 titled "Combination Immunotherapy and Chemotherapy for the Treatment of a Hematological Malignancy" will have a patent term running into January 2039. The Canadian patent issuing from Application No. 3,078,963 titled "Anti-CD45-Based Conditioning Methods and Uses Thereof in Conjunction with Gene-Edited Cell-Based Therapies" will have a patent term running into October 2038. The allowances build on protection already secured in other major markets, including a previously granted Japanese patent for the Actimab-A program and an issued U.S. patent for the Iomab-ACT program, with additional applications pending in the United States, Europe and China. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225.

Elevate Service Group Reports Q1 2026 Results and Rapid Expansion of National Facility Services Platform

(TSXV:SERV) Elevate Service Group Inc. announced that it has filed its quarterly financial statements for the fiscal quarter ended March 31, 2026, along with the related MD&A and CEO and CFO certifications. The company reported trailing twelve-month revenue of $38.2 million and Adjusted EBITDA of $4.2 million, with Q1 2026 revenue at $7.6 million and consolidated gross margins of 33%. Q1 2026 loss from operations was $0.9 million, and the company reported $4.9 million of cash, $14.8 million of total current assets, and $7.4 million of total current liabilities. Pro forma annualized revenue is approximately $90 million with pro forma Adjusted EBITDA margins of 12%, reflecting all acquisitions to date. The company completed four acquisitions since November 2025, including Infinity Group Construction Inc., First Choice Maintenance Inc., Charged Electric Services Ltd., TFI Food Equipment Solutions, Think Green Solutions, and JJ&A Mechanical. Elevate has more than 130 internal technicians and has hired over 10 new plumbing and electrical technicians in Southern Ontario during Q1 2026. The company projects continued organic growth, operational excellence, margin expansion, and intends to pursue additional acquisition opportunities.

Galloper Gold Closes Fully Funded $2.2M Non-Brokered Private Placement

(CSE: BOOM) Galloper Gold Corp. has closed its non-brokered private placement raising $2,226,996 in gross proceeds. The financing consisted of 16,891,633 flow-through common shares at $0.12 per FT Share for gross proceeds of $2,026,996, and 2,000,000 common shares at $0.10 per Share for gross proceeds of $200,000. Finder's fees totaling $71,890 in cash were paid to BMO Nesbitt Burns Inc., Canaccord Genuity Corp. and Ventum Financial Corp. All securities issued under the Private Placement will be subject to statutory hold periods pursuant to securities laws in Canada, including the statutory Restricted Period prescribed by Section 2.5 of National Instrument 45-102 Resale of Securities. The Company intends to use the net proceeds from the Private Placement for its 2026 exploration program at its Glover Island Property and for general working capital purposes. Galloper is focused on mineral exploration in the Central Newfoundland Gold Belt with its flagship Glover Island Property, 24 km southeast of Corner Brook. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

Company News in Context